ELVN

Enliven Therapeutics (ELVN)

About Enliven Therapeutics (ELVN)

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Details

Daily high

$16.85

Daily low

$16.47

Price at open

$16.67

52 Week High

$25.37

52 Week Low

$13.30

Market cap

992.9M

Dividend yield

0.00%

Volume

349,610

Avg. volume

817,484

P/E ratio

-9.06

Enliven Therapeutics News